Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein

Autor: Navis, Anna C, van Lith, Sanne A M, van Duijnhoven, Sander M J, de Pooter, Maaike, Yetkin-Arik, Bahar, Wesseling, Pieter, Hendriks, Wiljan J A J, Venselaar, Hanka, Timmer, Marco, van Cleef, Patricia, van Bergen En Henegouwen, Paul, Best, Myron G, Wurdinger, Thomas D, Tops, Bastiaan B J, Leenders, William P J, Celbiologie, Sub Cell Biology
Přispěvatelé: Neurosurgery, Celbiologie, Sub Cell Biology, Pathology, CCA - Oncogenesis
Rok vydání: 2015
Předmět:
Male
Protein Conformation
Pyridines
Messenger
RNA
Messenger/metabolism

Messenger/metabolism
medicine.disease_cause
Castration-Resistant
Proto-Oncogene Proteins c-met/antagonists & inhibitors
Exon
Mice
Taverne
Anilides
Non-U.S. Gov't
Sequence Deletion
Medicine(all)
Pyridines/pharmacology
Mutation
Tumor
Hepatocyte Growth Factor
Research Support
Non-U.S. Gov't

Sarcoma
Glioma
Proto-Oncogene Proteins c-met
Ligand (biochemistry)
Protein subcellular localization prediction
Transmembrane protein
Anilides/pharmacology
Intracellular location
Prostatic Neoplasms
Castration-Resistant

MET
Female
Tyrosine kinase
Antibodies/metabolism
Clinical Neurology
Hepatocyte Growth Factor/metabolism
Sarcoma/genetics
Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]
Biology
Research Support
Antibodies
Pathology and Forensic Medicine
Cell Line
Cellular and Molecular Neuroscience
Prostatic Neoplasms
Castration-Resistant/genetics

Cell Line
Tumor

medicine
Journal Article
Animals
Humans
splice
RNA
Messenger

Protein Kinase Inhibitors
Original Paper
Protein localization
Carcinoma
Prostatic Neoplasms
Genetic deletion
Biomarker
Molecular biology
Carcinoma/genetics
Castration-Resistant/genetics
Protein Kinase Inhibitors/pharmacology
Glioma/drug therapy
Cancer research
RNA
Neurology (clinical)
Neoplasm Grading
Nanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]
Neoplasm Transplantation
Auto-active
Zdroj: Navis, A C, van Lith, S A M, van Duijnhoven, S M J, de Pooter, M, Yetkin-Arik, B, Wesseling, P, Hendriks, W J A J, Venselaar, H, Timmer, M, van Cleef, P, Henegouwen, P V E, Best, M G, Würdinger, T, Tops, B B J & Leenders, W P J 2015, ' Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein ', Acta Neuropathologica, vol. 130, no. 1, pp. 131-144 . https://doi.org/10.1007/s00401-015-1420-5
Acta Neuropathologica
Acta neuropathologica, 130(1), 131-44. Springer Verlag
Acta Neuropathologica, 130(1), 131-144. Springer Verlag
Acta Neuropathologica, 130(1), 131. Springer Verlag
Acta Neuropathologica, 130, 131-44
Acta Neuropathologica, 130, 1, pp. 131-44
ISSN: 0001-6322
Popis: Contains fulltext : 153045.pdf (Publisher’s version ) (Open Access) MET has gained interest as a therapeutic target for a number of malignancies because of its involvement in tumorigenesis, invasion and metastasis. At present, a number of inhibitors, both antibodies against MET or its ligand hepatocyte growth factor, and small molecule MET tyrosine kinase inhibitors are in clinical trials. We here describe a novel variant of MET that is expressed in 6 % of high-grade gliomas. Characterization of this mutation in a glioma cell line revealed that it consists of an intronic deletion, resulting in a splice event connecting an intact splice donor site in exon 6 with the next splice acceptor site being that of exon 9. The encoded protein lacks parts of the extracellular IPT domains 1 and 2, encoded by exons 7 and 8, resulting in a novel pseudo-IPT and is named MET(Delta7-8). MET(Delta7-8) is located predominantly in the cytosol and is constitutively active. The auto-activating nature of MET(Delta7-8), in combination with a lack of transmembrane localization, renders MET(Delta7-8) not targetable using antibodies, although the protein is efficiently deactivated by MET-specific tyrosine kinase inhibitors. Testing of MET-expressing tumors for the presence of this variant may be important for treatment decision making.
Databáze: OpenAIRE